๐Ÿ‡ฎ๐Ÿ‡ชIreland
16ยฐC Partly Cloudy ยท Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Malignant Neoplasm
Clinical trial register · China

Malignant Neoplasm Trials in China, 2026

Every study on the ClinicalTrials.gov registry that lists a site in China and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage โ€” all 19052 matching records held by the registry are in this view. Synced 22 Sep 2026, 11:10 UTC
19052
Studies in scope
all four open statuses
11786
Recruiting now
open to new participants
2009
Lead sponsors
across recruiting studies
Top sites
Beijing 5 Fuzhou 4 Wuhan 4 Changsha 3 Chengdu 3
Narrow the registerReset
Recruitment status
Phase
Site location
Beijing5 Fuzhou4 Wuhan4 Changsha3 Chengdu3
All 17 locations
Target enrolment
to

Malignant Neoplasm trials in China

14 of 19052 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
Chinese sites
Start
Not yet open
Clinical Application of FAP-Targeted Radionuclide Imaging in the Diagnosis and Staging of Malignant Solid Tumors
NCT07707999Malignant Neoplasm
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Phase EARLY_PHASE1
20
Wuhan
2026-07-30
Recruiting
Cadherin 3(CDH3)-Targeted PET in Lung Malignant Tumors
NCT07487883Non-Small Cell Lung Cancer, Malignant Neoplasm, Pulmonary Nodules, PET/CT
Peking University People's Hospital
Observational
80
Beijing
2026-03-18
Recruiting
Construction and Evaluation of Tumor Immunotherapy and Organ Damage Early Warning System Based on Multi-omics
NCT07131007Malignant Neoplasm, Organ Damage
Hebei Medical University Fourth Hospital
Observational
2,000
Shijiazhuang
2025-09-15
Recruiting
A Study to Evaluate the Safety and Efficacy of MK-3120 in Participants With Advanced Solid Tumors (MK-3120-002)
NCT06818643Advanced Solid Tumors, Malignant Neoplasm
Merck Sharp & Dohme LLC
Phase 1/2
270
Beijing, Chongqing, Changsha, Changchun, Chengdu
2025-03-25
Recruiting
68Ga-JH12 PET/CT: Dosimetry and Biodistribution Study
NCT06688188Malignant Neoplasm
First Affiliated Hospital of Fujian Medical University
Phase EARLY_PHASE1
5
Fuzhou
2024-11-01
Recruiting
68Ga-NI-FAPI PET/CT: First-in-human Study
NCT06688305Malignant Neoplasm
First Affiliated Hospital of Fujian Medical University
Phase EARLY_PHASE1
40
Fuzhou
2024-08-01
Recruiting
18F-FAPIBiotin PET/CT: Dosimetry and Biodistribution Study
NCT06734572Malignant Neoplasm
First Affiliated Hospital of Fujian Medical University
Phase EARLY_PHASE1
5
Fuzhou
2024-06-25
Recruiting
A Study of TSN1611 Treating Patients With Advanced Solid Tumors Harboring KRAS G12D Mutation
NCT06385925Malignant Neoplasm
Tyligand Pharmaceuticals (Suzhou) Limited
Phase 1/2
440
Hefei, Beijing, Guangzhou, Wuhan, Changsha, Nanchang, Linyi, Shanghai
2024-04-29
Recruiting
68Ga-JH04 PET/CT: Dosimetry and Biodistribution Studies
NCT06438250Malignant Neoplasm
First Affiliated Hospital of Fujian Medical University
Phase EARLY_PHASE1
5
Fuzhou
2024-03-01
Recruiting
NV-001 in the Treatment of Advanced Solid Tumors
NCT06051760Malignant Neoplasm
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Phase 1
20
Beijing
2023-12-01
Recruiting
Integrin ฮฑvฮฒ6-targeted PET in Malignant Tumors
NCT05835570Malignant Neoplasm, PET/CT, Non-Small Cell Lung Cancer, Breast Cancer, Metastatic
Zhongnan Hospital
Observational
200
Wuhan
2023-01-01
Recruiting
PM8002 in the Treatment of Patients With Advanced Solid Tumors
NCT05918445Malignant Neoplasm
Biotheus Inc.
Phase 1/2
380
Baoji, Beijing, Changchun, Changde, Changsha, Changzhou, Chengdu, Chongqing
2021-03-09
Recruiting
68Ga-FAPI PET/CT in Malignant Tumors
NCT05034146Fibroblast Activation Protein Inhibitor, PET/CT, Malignant Neoplasm
Zhongnan Hospital
Not applicable
500
Wuhan
2021-02-23
Rows per page Showing 1–14 of 14
1
Cite this view

Priya Life Science (2026). Clinical trial register: studies with a Chinese investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 25 September 2026. https://priyalifescience.com/clinical-trials-china/condition/malignant-neoplasm

Query this register directly
GET /api/trials?country=cn&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every study on the registry that lists at least one investigative site in China and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 19,052 studies in total at the last sync on 22 Sep 2026, 11:10 UTC. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 14 of those studies listing the condition Malignant Neoplasm.

How many Malignant Neoplasm trials are recruiting in China?

13 of the 14 studies on this page are recruiting new participants as of the 22 Sep 2026, 11:10 UTC sync. A further 1 have not yet opened recruitment, 0 are active but closed to new participants, and 0 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Summary by phase

Studies by phase (Malignant Neoplasm), 14 studies
PhaseStudiesRecruitingShare
Phase EARLY_PHASE15435.7%
Observational3321.4%
Phase 1/23321.4%
Not applicable117.1%
Phase 1117.1%
Phase 2117.1%

Most active sponsors

Lead sponsors with the most studies (Malignant Neoplasm)
Lead sponsorStudiesRecruiting
First Affiliated Hospital of Fujian Medical University44
Merck Sharp & Dohme LLC22
Zhongnan Hospital22
Biotheus Inc.11
Cancer Institute and Hospital, Chinese Academy of Medical Sciences11
Hebei Medical University Fourth Hospital11
Peking University People's Hospital11
Tyligand Pharmaceuticals (Suzhou) Limited11
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology10
Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and India registers.